In her latest On target column, author Elena Garralda, Executive Director of VHIO’s Research Unit for Molecular Therapy of Cancer (UITM) – CaixaResearch, and Principal Investigator of our Early Clinical Drug Development Group, briefly discusses the results of just some of the many important studies that were presented at this month’s Annual Meeting of the American Society of Clinical Oncology (ASCO), 2-6 June, Chicago.
Published by the ESMO Daily Reporter, ESMO’s official newspaper, this month’s column—On the horizon of translational research—covers four different contributions that made headlines during the meeting. Specifically, Elena highlights results from the phase III SONIA study (LBA 1000), the ongoing phase II DESTINY-PanTumor-02 trial (LBA 3000) and phase II RAGNAR (Abstract 3121) trials, and preliminary data of a first-in-human, phase I dose-escalation adaptive two-part study (Abstract 3020).
To discover more, we invite you to read Elena’s latest column here, and browse all the previous editions by clicking here.
